The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma.

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by production of abnormal levels of a monoclonal immunoglobulin or plasma cell deposition that leads to end organ destruction. The disease remains incurable despite advances in combination treatments with classes of medications that include proteosome inhibitors, immunomodulating agents, monoclonal antibodies, small molecule inhibitors, alkylating agents, T-cell-based immunotherapies, and others. Checkpoint inhibitors (CKP-I), though showing robust efficacy in solid tumor and lymphoma, have had limited success as single agents in the treatment of MM.

Renal Artery Thrombosis Leading to Renal Infarct in a Patient With Recurrent Nephrolithiasis.

Renal infarction is a rare entity that presents similarly to other common renal conditions such as nephrolithiasis, which can often result in a missed or delayed diagnosis. As a result, a high degree of suspicion for this diagnosis is warranted in patients presenting with flank pain. We present a patient with recurrent nephrolithiasis who presented with flank pain.

Diagnostic and Management Considerations in a Patient With Primary Pulmonary Meningioma With Associated Micro-Solid Nodules.

Primary pulmonary meningiomas (PPMs) are rare mesodermal tumors that arise in the lung and are most often incidentally identified as single pulmonary nodules. Most cases of PPM are benign, and surgical resection remains the primary curative treatment. We describe the case of a 65-year-old asymptomatic female who presented with an incidentally identified 2.

Adverse Events After Left Atrial Appendage Closure: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Database.

Left atrial appendage (LAA) closure devices are alternative treatments recently approved for patients with atrial fibrillation. Due to the novelty of these devices, limited postapproval surveillance data on LAA closure devices have been published. Thus, we analyzed the United States Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database to report these findings.